Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IVIG for neonatal hemolytic jaundice
IRCT20171218037936N3Phase 3Completed
- Sponsor
- Urmia University of Medical Sciences
- Start
- May 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of immune globulin in Erythroblastosis fetalis (HDFN) and jaundice (3 arms), sponsored by Urmia University of Medical Sciences. Primary endpoints: Length of stay, Duration of phototherapy and 3 more. Started May 2019; status: completed.
02
Drugs
immune globulin
03
Conditions
Erythroblastosis fetalis (HDFN)jaundice
Beyond the preview
Go deeper on IRCT20171218037936N3.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20171218037936N3.